Key issues in the pharmaceutical industry: consequences on R&D

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.4, Iss.1, 2009-01, pp. : 15-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Measuring US Pharmaceutical Industry R&D Spending

By Golec Joseph Vernon John

PharmacoEconomics, Vol. 26, Iss. 12, 2008-01 ,pp. : 1005-1017

Adis International

Access to resources Recommend Favorite

Considering the economic principles of pharmaceutical R&D

By Vernon John A

Expert Opinion on Drug Discovery, Vol. 4, Iss. 1, 2009-01 ,pp. : 21-22

Informa Healthcare

Access to resources Recommend Favorite

Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms

By Golec Joseph Vernon John A.

PharmacoEconomics, Vol. 28, Iss. 8, 2010-08 ,pp. : 615-628

Adis International

Access to resources Recommend Favorite

Recent R&D Highlights

Pharmaceutical Innovation, Vol. 12, Iss. 3, 2003-04 ,pp. : 34-36

Adis International

Access to resources Recommend Favorite

Recent R&D Highlights

Pharmaceutical & Diagnostic Innovation, Vol. 1, Iss. 3, 2004-01 ,pp. : 28-29

Adis International

Access to resources Recommend Favorite